SynthesisFrontiers in pharmacology2025
The anti-osteoporotic effect of puerarin on the femoral bone in rat models of osteoporosis: a systematic review and meta-analysis.
Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Protective effects and mechanisms of puerarin in ovariectomized animal models of osteoporosis: a systematic review and meta-analysis of preclinical studies.Frontiers in physiology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: In this systematic review and meta-analysis, we aimed to evaluate the anti-osteoporotic efficacy of puerarin in rodent models of osteoporosis (OP) and to explore the impact of the dosage, treatment duration, and intervention method. Methods: A comprehensive search of electronic databases (e.g., PubMed, Embase, Web of Science, CNKI, and Wanfang) was conducted through August 2025. Randomized controlled trials investigating the effects of puerarin monotherapy on osteoporotic rats were included. The primary outcome measured was bone mineral density (BMD), and the secondary outcomes included bone histomorphometric parameters (BV/TV, Tb.Th, Tb.N, and Tb.Sp) and bone turnover markers (e.g., PINP, BALP, CTX, TRACP, and osteocalcin). Data were pooled using a random-effects model, and subgroup analyses were performed based on the puerarin dose, treatment duration, and intervention method. The study quality was assessed using the SYRCLE risk-of-bias tool. Results: Twenty-eight studies involving 570 animals were included. The meta-analysis demonstrated that puerarin significantly increased femoral BMD (SMD = 2.95, 95% CI: 2.32 to 3.58, and p < 0.00001) and improved the bone microarchitecture by increasing BV/TV, Tb.Th, and Tb.N, and decreasing Tb.Sp. Subgroup analysis revealed that the most pronounced BMD improvement occurred at doses ≥50 mg/kg/day administered for ≥8 weeks. Puerarin significantly suppressed bone resorption markers, CTX and TRACP, and elevated serum levels of osteocalcin, calcium, and phosphorus. However, its effects on bone formation markers, PINP and BALP, were not statistically significant. Conclusion: Puerarin exhibits significant therapeutic potential for OP in rat models by increasing BMD, improving bone quality, and rebalancing bone metabolism in favor of formation, primarily through the inhibition of resorption. The optimal effect appears to be dose- and duration-dependent. Although these preclinical findings are promising, the clinical translation of puerarin requires validation through larger-scale, high-quality animal studies and subsequent clinical trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.